These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 22253738

  • 21. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing.
    Chen CJ, Lin MH, Shu JC, Lu JJ.
    J Antimicrob Chemother; 2014 Feb; 69(2):349-54. PubMed ID: 24092658
    [Abstract] [Full Text] [Related]

  • 22. Insights into the molecular basis of reduced vancomycin susceptibility among three prominent Staphylococcus aureus clonal complexes.
    Malachowa N, Sturdevant DE, Porter AR, Martin G, Martens C, Nair V, Hansen B, Ricklefs S, Jenkins SG, Chen L, Kreiswirth BN, DeLeo FR.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0048624. PubMed ID: 38916317
    [Abstract] [Full Text] [Related]

  • 23. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K.
    Antimicrob Agents Chemother; 2009 Aug 06; 53(8):3190-6. PubMed ID: 19451283
    [Abstract] [Full Text] [Related]

  • 24. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.
    Antimicrob Agents Chemother; 2013 Jan 06; 57(1):66-73. PubMed ID: 23070161
    [Abstract] [Full Text] [Related]

  • 25. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG, Gao W, Ward PB, Howden BP.
    J Antimicrob Chemother; 2011 May 06; 66(5):1057-60. PubMed ID: 21393156
    [Abstract] [Full Text] [Related]

  • 26. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.
    Cui L, Tominaga E, Neoh HM, Hiramatsu K.
    Antimicrob Agents Chemother; 2006 Mar 06; 50(3):1079-82. PubMed ID: 16495273
    [Abstract] [Full Text] [Related]

  • 27. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu TL, Wang JT.
    J Microbiol Immunol Infect; 2016 Oct 06; 49(5):701-707. PubMed ID: 26320398
    [Abstract] [Full Text] [Related]

  • 28. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
    Hu J, Ma XX, Tian Y, Pang L, Cui LZ, Shang H.
    PLoS One; 2013 Oct 06; 8(9):e73300. PubMed ID: 24069184
    [Abstract] [Full Text] [Related]

  • 29. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A, Chaiyapoke C, Booncharoen S, Wongthong S, Chanawong A, Tippayawat P, Tavichakorntrakool R, Lulitanond A.
    Turk J Med Sci; 2021 Aug 30; 51(4):2150-2158. PubMed ID: 33705643
    [Abstract] [Full Text] [Related]

  • 30. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.
    McEvoy CR, Tsuji B, Gao W, Seemann T, Porter JL, Doig K, Ngo D, Howden BP, Stinear TP.
    Antimicrob Agents Chemother; 2013 Jul 30; 57(7):3240-9. PubMed ID: 23629723
    [Abstract] [Full Text] [Related]

  • 31. An induced mutation of ABC-transporter component VraF(K84E) contributes to vancomycin resistance and virulence in Staphylococcus aureus strain MW2.
    Cao R, Su H, Wei Z, He Z, Pan T, Li Y, Sun B.
    Int J Med Microbiol; 2024 Jun 30; 315():151624. PubMed ID: 38838390
    [Abstract] [Full Text] [Related]

  • 32. Staphylococcus aureus response and adaptation to vancomycin.
    Fait A, Silva SF, Abrahamsson JÅH, Ingmer H.
    Adv Microb Physiol; 2024 Jun 30; 85():201-258. PubMed ID: 39059821
    [Abstract] [Full Text] [Related]

  • 33. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus.
    Cafiso V, Bertuccio T, Purrello S, Campanile F, Mammina C, Sartor A, Raglio A, Stefani S.
    Int J Antimicrob Agents; 2014 Jan 30; 43(1):26-31. PubMed ID: 24183798
    [Abstract] [Full Text] [Related]

  • 34. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K.
    Antimicrob Agents Chemother; 2008 Jan 30; 52(1):45-53. PubMed ID: 17954695
    [Abstract] [Full Text] [Related]

  • 35. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2014 Jan 30; 58(2):672-7. PubMed ID: 24217694
    [Abstract] [Full Text] [Related]

  • 36. A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus.
    Zhu J, Liu B, Shu X, Sun B.
    Int J Med Microbiol; 2021 Feb 30; 311(2):151473. PubMed ID: 33445057
    [Abstract] [Full Text] [Related]

  • 37. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A, Aydın M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, Bayındır Bilmen F, Solmaz S, Özekinci T.
    Mikrobiyol Bul; 2015 Apr 30; 49(2):240-8. PubMed ID: 26167824
    [Abstract] [Full Text] [Related]

  • 38. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.
    Kang KM, Mishra NN, Park KT, Lee GY, Park YH, Bayer AS, Yang SJ.
    J Microbiol; 2017 Feb 30; 55(2):153-159. PubMed ID: 28120188
    [Abstract] [Full Text] [Related]

  • 39. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.
    Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Sep 30; 55(9):4188-95. PubMed ID: 21746940
    [Abstract] [Full Text] [Related]

  • 40. Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.
    Zhang S, Sun X, Chang W, Dai Y, Ma X.
    PLoS One; 2015 Sep 30; 10(8):e0136082. PubMed ID: 26287490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.